ArticleFrontiers in neurology2025
Evaluation of Siemens Healthineers' StrokeSegApp for automated diffusion and perfusion lesion segmentation in patients with ischemic stroke.
Article in Frontiers in neurology, 2025. The graph could read no effect estimate from its abstract, so it casts no vote on the map. It is linked to trial NCT00715533 (3T Stroke MRT for Examining Mismatch in the CSB of the Charité Universitätsmedizin Berlin), which is not on this map. Cited by 1 paper.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
3T Stroke MRT for Examining Mismatch in the CSB of the Charité Universitätsmedizin Berlin (3Tesla in 1000+)
Who cites it
1 citing paper in PubMed.
- Comparative validation of automated perfusion analysis software for ischemic penumbra estimation and EVT decision-making.Frontiers in neuroscience · 2025Article
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
7 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
Purpose: This study aimed to evaluate the perfomance of Siemens Healthineers' StrokeSegApp performance in automatically segmenting diffusion and perfusion lesions in patients with acute ischemic stroke and to assess its clinical utility in guiding mechanical thrombectomy decisions. Methods: This retrospective study used MRI data of acute ischemic stroke patients from the prospective observational single-center 1000Plus study, acquired between September 2008 and June 2013 (clinicaltrials.org; NCT00715533) and manually segmented by radiologists as the ground truth. The performance of the StrokeSegApp was compared against this ground truth using the dice similarity coefficient (DSC) and Bland-Altman plots. The study also evaluated the application's ability to recommend mechanical thrombectomy based on DEFUSE 2 and 3 trial criteria. Results: The StrokeSegApp demonstrated a mean DSC of 0.60 (95% CI: 0.57-0.63; Conclusion: The Siemens Healthineers' StrokeSegApp provides accurate automated segmentation of ischemic stroke lesions, comparable to human experts as well as similar commercial software, and shows potential as a reliable tool in clinical decision-making for stroke treatment.
Indexed as
Identifiers
What Socratic holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the Socratic graph.